NF-κB profiles of MM cell lines
| Systematic name . | NF-κB index (10) . | NF-κB mutation . | NF-κB pathway . |
|---|---|---|---|
| EJM | 11.81 | NIK | Both |
| ARP-1C* | 11.66 | NFKB2 | Mostly alternative |
| KMS20 | 11.64 | CIAP | Both |
| Kp6 | 11.38 | CYLD | Mostly classical |
| JMW1 | 11.36 | TRAF2 | Both |
| KMS28PE* | 11.24 | CIAP | Both |
| MM.1 | 11.24 | TRAF3 | Both |
| KMM1 | 11.19 | NFKB1 | Mostly classical |
| LP1 | 11.17 | TRAF3 | Both |
| KMS18 | 11.00 | CIAP | Both |
| XG2 | 10.99 | CD40 | Both |
| JK6L | 10.95 | NFKB2 | Mostly alternative |
| KMS12PE* | 10.91 | — | Mostly classical |
| JJN3 | 10.80 | NIK | Both |
| OciMy5 | 10.74 | NFKB1 | Mostly classical |
| OciMy1 | 10.70 | TRAF3 | Both |
| Karpas620 | 10.70 | — | Mostly classical |
| L363 | 10.44 | NIK | Both |
| RPMI8226 | 10.44 | TRAF3 | Both |
| U266 | 10.41 | TRAF3 | Both |
| KMS12BM* | 10.39 | — | Mostly classical |
| ANBL6 | 10.38 | TRAF3 | Both |
| KMS11 | 10.27 | TRAF3 | Both |
| KMS26 | 10.24 | TACI | Mostly classical |
| KMS28BM* | 10.09 | — | Weak classical |
| MM-S1 | 9.84 | — | Weak classical |
| H1112 | 9.72 | — | Weak classical |
| ARP-1* | 9.68 | — | Not done |
| KMS34 | 9.50 | — | Weak classical |
| OciMy7 | 9.19 | — | Not done |
| KHM1b | 9.17 | — | Not done |
| DP6 | 9.09 | — | Weak classical |
| FR4 | 9.06 | LTBR | Weak both |
| OPM2* | 9.03 | — | Weak classical |
| KHM11 | 8.97 | — | Weak classical |
| OPM1* | 8.88 | — | Not done |
| Sachi | 8.85 | — | Weak classical |
| Delta47 | 8.75 | — | Not done |
| UTMC2 | 8.68 | — | Not done |
| PE2 | 8.53 | — | Not done |
| SKMM1 | 8.47 | — | Weak both |
| H929 | 8.37 | — | Weak classical |
| JIM3 | 8.33 | — | Not done |
| FLAM76 | 8.30 | — | Weak classical |
| SKMM2 | 8.30 | — | Not done |
| INA6 | 8.26 | — | Weak classical |
| XG1 | 8.21 | — | Not done |
| KAS6.1 | 8.20 | — | Not done |
| XG6 | 8.13 | — | Not done |
| XG7 | 7.90 | — | Not done |
| PE1 | 7.79 | — | Weak classical |
| Systematic name . | NF-κB index (10) . | NF-κB mutation . | NF-κB pathway . |
|---|---|---|---|
| EJM | 11.81 | NIK | Both |
| ARP-1C* | 11.66 | NFKB2 | Mostly alternative |
| KMS20 | 11.64 | CIAP | Both |
| Kp6 | 11.38 | CYLD | Mostly classical |
| JMW1 | 11.36 | TRAF2 | Both |
| KMS28PE* | 11.24 | CIAP | Both |
| MM.1 | 11.24 | TRAF3 | Both |
| KMM1 | 11.19 | NFKB1 | Mostly classical |
| LP1 | 11.17 | TRAF3 | Both |
| KMS18 | 11.00 | CIAP | Both |
| XG2 | 10.99 | CD40 | Both |
| JK6L | 10.95 | NFKB2 | Mostly alternative |
| KMS12PE* | 10.91 | — | Mostly classical |
| JJN3 | 10.80 | NIK | Both |
| OciMy5 | 10.74 | NFKB1 | Mostly classical |
| OciMy1 | 10.70 | TRAF3 | Both |
| Karpas620 | 10.70 | — | Mostly classical |
| L363 | 10.44 | NIK | Both |
| RPMI8226 | 10.44 | TRAF3 | Both |
| U266 | 10.41 | TRAF3 | Both |
| KMS12BM* | 10.39 | — | Mostly classical |
| ANBL6 | 10.38 | TRAF3 | Both |
| KMS11 | 10.27 | TRAF3 | Both |
| KMS26 | 10.24 | TACI | Mostly classical |
| KMS28BM* | 10.09 | — | Weak classical |
| MM-S1 | 9.84 | — | Weak classical |
| H1112 | 9.72 | — | Weak classical |
| ARP-1* | 9.68 | — | Not done |
| KMS34 | 9.50 | — | Weak classical |
| OciMy7 | 9.19 | — | Not done |
| KHM1b | 9.17 | — | Not done |
| DP6 | 9.09 | — | Weak classical |
| FR4 | 9.06 | LTBR | Weak both |
| OPM2* | 9.03 | — | Weak classical |
| KHM11 | 8.97 | — | Weak classical |
| OPM1* | 8.88 | — | Not done |
| Sachi | 8.85 | — | Weak classical |
| Delta47 | 8.75 | — | Not done |
| UTMC2 | 8.68 | — | Not done |
| PE2 | 8.53 | — | Not done |
| SKMM1 | 8.47 | — | Weak both |
| H929 | 8.37 | — | Weak classical |
| JIM3 | 8.33 | — | Not done |
| FLAM76 | 8.30 | — | Weak classical |
| SKMM2 | 8.30 | — | Not done |
| INA6 | 8.26 | — | Weak classical |
| XG1 | 8.21 | — | Not done |
| KAS6.1 | 8.20 | — | Not done |
| XG6 | 8.13 | — | Not done |
| XG7 | 7.90 | — | Not done |
| PE1 | 7.79 | — | Weak classical |
An NF-κB index was calculated using the average expression of 10 NF-κB target genes (“Genes comprising the NF-κB index in myeloma”). Mutations were reported previously,15,16 except for 2 new mutations reported here: (1) biallelic deletion of TRAF2 in JMW1 and (2) mutation of CYLD gene in Kp6. Contribution of the classical and alternative NF-κB pathways in MMCLs was estimated from steady-state levels of NF-κB subunits and/or effect of IKKβ inhibitor.
— indicates no mutation identified.
It is not known whether different mutations in some pairs of cell lines represent different tumor subclones or occurred after generation of the cell lines.